Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Clearmind Medicine Files Three Provisional Patent Applications With USPTO

The applications for novel psychedelic-based combinations, developed with SciSparc, are based on monotherapy and novel combinations of SciSparc's Cannamide™ and classical psychedelics
byBill Haddad
February 15, 2023
1 minute read
Total
0
Shares
0
0
0
0
0
0

The applications for novel psychedelic-based combinations, developed with SciSparc, are based on monotherapy and novel combinations of SciSparc’s Cannamide™ and classical psychedelics

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

Aesthetics Market Resilience: AbbVie Asserts Widely Used Botox Dominance Amidst Rising Competition

By Vandana Singh
January 11, 9:31 AM
AbbVie Inc's (NYSE: ABBV) unwavering confidence in Botox's resilience within the aesthetics market with a commanding 68% market share remains steadfast. Despite a recent FDA petition addressing potential risks, AbbVie emphasizes its commitment to safety with existing 'black box' warnings. Amidst economic uncertainties and emerging competitors, AbbVie anticipates continued strength.

ABBV